Amwell (AMWL) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $54.9 million, down 18% year-over-year.

Subscription Revenue: $24.9 million, down 23% year-over-year due to churn, though renewals exceeded expectations.

Amwell Medical Group (AMG) Visit Revenue: $28.9 million, up 9% year-over-year, with paid visits totaling approximately 382,000.

Total Platform Visits: 1 million, down 19% year-over-year.

Gross Profit: $28 million with a gross margin of 51%, down from 52.8% in Q1 2025.

Operating Expenses: $45.4 million, down 31% year-over-year; improved as a percentage of revenue to 82.6%.

Adjusted EBITDA: Loss of $3.1 million, an improvement from a loss of $12.2 million in Q1 2025.

Cash Position: $179 million in cash and investments, with no debt; cash burn reduced to $3.1 million from $19 million in the previous quarter.

2Strategic Updates and Business Highlights

Amwell has focused on consolidating its platform to meet urgent customer needs, resulting in a renewed three-year contract with Elevance and a global deployment with the DHA.

The company aims to leverage AI and a unified data structure to enhance operational efficiency and improve clinical outcomes.

Significant operational improvements have been made, including a shift towards higher-margin SaaS offerings, which is expected to support margin expansion.

The regulatory environment is favorable, with CMS making telehealth flexibilities permanent, which is a tailwind for Amwell’s platform.

3Forward Guidance and Outlook

Q2 2026 Revenue Guidance: Expected between $48 million and $52 million, with an adjusted EBITDA loss projected between $4 million and $2 million.

Full Year 2026 Revenue Guidance: Reiterated at $195 million to $205 million, with an updated adjusted EBITDA loss forecast of $16 million to $12 million (previously $24 million to $18 million).

Confidence in achieving positive cash flow from operations by Q4 2026.

4Bad News, Challenges, or Points of Concern

Total revenue and subscription revenue declined year-over-year, primarily due to churn, which remains a concern.

Visit volumes were down compared to the previous year, although there was a positive trend in higher-value care.

The company faces challenges with vendor sprawl and the integration of point solutions, which complicates customer experiences.

Competitive pressures exist as customers are cautious about adopting AI features, preferring proven aspects of the platform.

5Notable Q&A Insights

Discussions around the DHA contract renewal indicated confidence in maintaining the relationship, with expectations for potential expansion in behavioral health services.

The pipeline for new opportunities is significantly larger than in previous years, with a focus on government contracts.

AI capabilities are increasingly discussed with clients, but the willingness to pay for these features varies, with many clients preferring to bundle them within existing platform pricing.

Management expressed optimism about future revenue growth in 2027, driven by new government contracts and a stable operational cost structure. Overall, Amwell's Q1 2026 results reflect a mix of challenges and strategic progress, with a focus on improving financial metrics and expanding its market presence through a unified platform and AI capabilities.